Pamidronate Treatment in Patients with Tumor-Associated Hypercalcemia: Pharmacological Effects and Pharmacokinetics

The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia. Eight patients with tumor-associated hypercalcemia received intravenous infusion of pamidronate (45 mg) a...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Journal 1994, Vol.41(6), pp.655-661
Main Authors: OISO, YUTAKA, TOMITA, AKIO, HASEGAWA, HARUHIKO, ARIYOSHI, YUTAKA, NIINOMI, MITSURO, YAMAMOTO, MASAHIRO, TAKANO, TSUNENORI, SAKIYAMA, NORIHISA
Format: Article
Language:English
Subjects:
Aged
Calcium - blood
Diphosphonates - administration & dosage
Diphosphonates - pharmacokinetics
Diphosphonates - therapeutic use
Female
Homeostasis
Humans
Hypercalcemia
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Infusions, Intravenous
Kinetics
Male
Middle Aged
Neoplasms - complications
Osteocalcin - blood
Pamidronate
Parathyroid Hormone - blood
Parathyroid Hormone-Related Protein
Pharmacokinetics
Proteins - metabolism
PTH related peptide
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to investigate the effects of pamidronate, a second generation bisphosphonate, on the change in calcium homeostasis in patients with tumor-associated hypercalcemia. Eight patients with tumor-associated hypercalcemia received intravenous infusion of pamidronate (45 mg) and their high mean serum calcium concentration significantly decreased from 3.56 mmol/L to 2.62 mmol/L 7 days after treatment. Serum intact PTH before treatment had been suppressed to below normal in all patients but returned to normal range in six patients within 7 days after treatment. Urinary PTH related peptide (PTHrP) excretion before treatment had been elevated in seven patients and then significantly increased further after pamidronate therapy. The serum bone Gla protein concentration was not apparently changed by the treatment. Pamidronate in serum was rapidly eliminated after the treatment and urinary excretion reached a plateau on the second day (13.8% of the administered dose), suggesting that the major portion of the infused dose had been distributed to the bone and other tissues. These findings suggest that pamidronate has a potent hypocalcemic effect and that PTHrP production in malignant tumors could be affected by pamidronate therapy.
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.41.655